Effect of EPI-743 on the clinical course of the mitochondrial disease leber hereditary optic neuropathy

Alfredo A. Sadun, Carlos Filipe Chicani, Fred N. Ross-Cisneros, Piero Barboni, Martin Thoolen, William D. Shrader, Kenneth Kubis, Valerio Carelli, Guy Miller

Research output: Contribution to journalArticle

109 Citations (Scopus)

Abstract

Objective: To evaluate the safety and efficacy of a new therapeutic agent, EPI-743, in Leber hereditary optic neuropathy (LHON) using standard clinical, anatomic, and functional visual outcome measures. Design: Open-label clinical trial. Setting: University medical center. Patients: Five patients with genetically confirmedLHON with acute loss of vision were consecutively enrolled and treated with the experimental therapeutic agent EPI- 743 within 90 days of conversion. Intervention: During the course of the study, 5 consecutive patients received EPI-743, by mouth, 3 times daily (100-400 mg per dose). Main Outcome Measures: Treatment effect was assessed by serial measurements of anatomic and functional visual indices over 6 to 18 months, including Snellen visual acuity, retinal nerve fiber layer thicknessmeasured by optical coherence tomography, Humphrey visual fields (mean decibels and area with 1-log unit depression), and color vision. Treatment effect in this clinical proof of principle study was assessed by comparison of the prospective open-label treatment group with historical controls. Results: Of 5 subjects treated with EPI-743, 4 demonstrated arrest of disease progression and reversal of visual loss. Two patients exhibited a total recovery of visual acuity. No drug-related adverse events were recorded. Conclusions: In a small open-label trial, EPI-743 arrested disease progression and reversed vision loss in all but 1 of the 5 consecutively treated patients with LHON. Given the known natural history of acute and rapid progression of LHON resulting in chronic and persistent bilateral blindness, these data suggest that the previously described irreversible priming to retinal ganglion cell loss may be reversed.

Original languageEnglish
Pages (from-to)331-338
Number of pages8
JournalArchives of Neurology
Volume69
Issue number3
DOIs
Publication statusPublished - Mar 2012

Fingerprint

Leber's Hereditary Optic Atrophy
Mitochondrial Diseases
Visual Acuity
Disease Progression
Outcome Assessment (Health Care)
Therapeutics
Color Vision
Retinal Ganglion Cells
Optical Coherence Tomography
Blindness
Drug-Related Side Effects and Adverse Reactions
Visual Fields
Natural History
Nerve Fibers
Mouth
alpha-tocotrienol quinone
Optics
Hereditary Disease
Clinical Trials
Depression

ASJC Scopus subject areas

  • Clinical Neurology
  • Arts and Humanities (miscellaneous)

Cite this

Sadun, A. A., Chicani, C. F., Ross-Cisneros, F. N., Barboni, P., Thoolen, M., Shrader, W. D., ... Miller, G. (2012). Effect of EPI-743 on the clinical course of the mitochondrial disease leber hereditary optic neuropathy. Archives of Neurology, 69(3), 331-338. https://doi.org/10.1001/archneurol.2011.2972

Effect of EPI-743 on the clinical course of the mitochondrial disease leber hereditary optic neuropathy. / Sadun, Alfredo A.; Chicani, Carlos Filipe; Ross-Cisneros, Fred N.; Barboni, Piero; Thoolen, Martin; Shrader, William D.; Kubis, Kenneth; Carelli, Valerio; Miller, Guy.

In: Archives of Neurology, Vol. 69, No. 3, 03.2012, p. 331-338.

Research output: Contribution to journalArticle

Sadun, AA, Chicani, CF, Ross-Cisneros, FN, Barboni, P, Thoolen, M, Shrader, WD, Kubis, K, Carelli, V & Miller, G 2012, 'Effect of EPI-743 on the clinical course of the mitochondrial disease leber hereditary optic neuropathy', Archives of Neurology, vol. 69, no. 3, pp. 331-338. https://doi.org/10.1001/archneurol.2011.2972
Sadun, Alfredo A. ; Chicani, Carlos Filipe ; Ross-Cisneros, Fred N. ; Barboni, Piero ; Thoolen, Martin ; Shrader, William D. ; Kubis, Kenneth ; Carelli, Valerio ; Miller, Guy. / Effect of EPI-743 on the clinical course of the mitochondrial disease leber hereditary optic neuropathy. In: Archives of Neurology. 2012 ; Vol. 69, No. 3. pp. 331-338.
@article{146389e5d74f458590a351e96341638e,
title = "Effect of EPI-743 on the clinical course of the mitochondrial disease leber hereditary optic neuropathy",
abstract = "Objective: To evaluate the safety and efficacy of a new therapeutic agent, EPI-743, in Leber hereditary optic neuropathy (LHON) using standard clinical, anatomic, and functional visual outcome measures. Design: Open-label clinical trial. Setting: University medical center. Patients: Five patients with genetically confirmedLHON with acute loss of vision were consecutively enrolled and treated with the experimental therapeutic agent EPI- 743 within 90 days of conversion. Intervention: During the course of the study, 5 consecutive patients received EPI-743, by mouth, 3 times daily (100-400 mg per dose). Main Outcome Measures: Treatment effect was assessed by serial measurements of anatomic and functional visual indices over 6 to 18 months, including Snellen visual acuity, retinal nerve fiber layer thicknessmeasured by optical coherence tomography, Humphrey visual fields (mean decibels and area with 1-log unit depression), and color vision. Treatment effect in this clinical proof of principle study was assessed by comparison of the prospective open-label treatment group with historical controls. Results: Of 5 subjects treated with EPI-743, 4 demonstrated arrest of disease progression and reversal of visual loss. Two patients exhibited a total recovery of visual acuity. No drug-related adverse events were recorded. Conclusions: In a small open-label trial, EPI-743 arrested disease progression and reversed vision loss in all but 1 of the 5 consecutively treated patients with LHON. Given the known natural history of acute and rapid progression of LHON resulting in chronic and persistent bilateral blindness, these data suggest that the previously described irreversible priming to retinal ganglion cell loss may be reversed.",
author = "Sadun, {Alfredo A.} and Chicani, {Carlos Filipe} and Ross-Cisneros, {Fred N.} and Piero Barboni and Martin Thoolen and Shrader, {William D.} and Kenneth Kubis and Valerio Carelli and Guy Miller",
year = "2012",
month = "3",
doi = "10.1001/archneurol.2011.2972",
language = "English",
volume = "69",
pages = "331--338",
journal = "Archives of Neurology",
issn = "0003-9942",
publisher = "American Medical Association",
number = "3",

}

TY - JOUR

T1 - Effect of EPI-743 on the clinical course of the mitochondrial disease leber hereditary optic neuropathy

AU - Sadun, Alfredo A.

AU - Chicani, Carlos Filipe

AU - Ross-Cisneros, Fred N.

AU - Barboni, Piero

AU - Thoolen, Martin

AU - Shrader, William D.

AU - Kubis, Kenneth

AU - Carelli, Valerio

AU - Miller, Guy

PY - 2012/3

Y1 - 2012/3

N2 - Objective: To evaluate the safety and efficacy of a new therapeutic agent, EPI-743, in Leber hereditary optic neuropathy (LHON) using standard clinical, anatomic, and functional visual outcome measures. Design: Open-label clinical trial. Setting: University medical center. Patients: Five patients with genetically confirmedLHON with acute loss of vision were consecutively enrolled and treated with the experimental therapeutic agent EPI- 743 within 90 days of conversion. Intervention: During the course of the study, 5 consecutive patients received EPI-743, by mouth, 3 times daily (100-400 mg per dose). Main Outcome Measures: Treatment effect was assessed by serial measurements of anatomic and functional visual indices over 6 to 18 months, including Snellen visual acuity, retinal nerve fiber layer thicknessmeasured by optical coherence tomography, Humphrey visual fields (mean decibels and area with 1-log unit depression), and color vision. Treatment effect in this clinical proof of principle study was assessed by comparison of the prospective open-label treatment group with historical controls. Results: Of 5 subjects treated with EPI-743, 4 demonstrated arrest of disease progression and reversal of visual loss. Two patients exhibited a total recovery of visual acuity. No drug-related adverse events were recorded. Conclusions: In a small open-label trial, EPI-743 arrested disease progression and reversed vision loss in all but 1 of the 5 consecutively treated patients with LHON. Given the known natural history of acute and rapid progression of LHON resulting in chronic and persistent bilateral blindness, these data suggest that the previously described irreversible priming to retinal ganglion cell loss may be reversed.

AB - Objective: To evaluate the safety and efficacy of a new therapeutic agent, EPI-743, in Leber hereditary optic neuropathy (LHON) using standard clinical, anatomic, and functional visual outcome measures. Design: Open-label clinical trial. Setting: University medical center. Patients: Five patients with genetically confirmedLHON with acute loss of vision were consecutively enrolled and treated with the experimental therapeutic agent EPI- 743 within 90 days of conversion. Intervention: During the course of the study, 5 consecutive patients received EPI-743, by mouth, 3 times daily (100-400 mg per dose). Main Outcome Measures: Treatment effect was assessed by serial measurements of anatomic and functional visual indices over 6 to 18 months, including Snellen visual acuity, retinal nerve fiber layer thicknessmeasured by optical coherence tomography, Humphrey visual fields (mean decibels and area with 1-log unit depression), and color vision. Treatment effect in this clinical proof of principle study was assessed by comparison of the prospective open-label treatment group with historical controls. Results: Of 5 subjects treated with EPI-743, 4 demonstrated arrest of disease progression and reversal of visual loss. Two patients exhibited a total recovery of visual acuity. No drug-related adverse events were recorded. Conclusions: In a small open-label trial, EPI-743 arrested disease progression and reversed vision loss in all but 1 of the 5 consecutively treated patients with LHON. Given the known natural history of acute and rapid progression of LHON resulting in chronic and persistent bilateral blindness, these data suggest that the previously described irreversible priming to retinal ganglion cell loss may be reversed.

UR - http://www.scopus.com/inward/record.url?scp=84858599179&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858599179&partnerID=8YFLogxK

U2 - 10.1001/archneurol.2011.2972

DO - 10.1001/archneurol.2011.2972

M3 - Article

VL - 69

SP - 331

EP - 338

JO - Archives of Neurology

JF - Archives of Neurology

SN - 0003-9942

IS - 3

ER -